Skip to content

Metabolic Modulators

Tirzepatide

Weekly dual GIP/GLP-1 agonist producing the largest average weight loss of approved obesity drugs; lean-mass protection still matters.

FDA approvedEvidence level 5 of 5: FDA-approved / large RCTsAlso: Mounjaro, Zepbound, LY3298176

Overview

Tirzepatide is a single peptide that activates two incretin receptors: GIP and GLP-1. Combining both signals enhances insulin release, suppresses appetite and slows stomach emptying, and GIP may further improve fat-tissue metabolism and tolerability. A fatty-acid chain gives it a roughly five-day half-life for weekly dosing. In the SURMOUNT trials, the highest dose produced about 21% average weight loss over 72 weeks, and a head-to-head study found it outperformed semaglutide. It is approved for type 2 diabetes, obesity and obstructive sleep apnea. As with all incretin drugs, protein intake, resistance training and a plan for maintenance are essential.

Classification
Dual GIP/GLP-1 receptor agonist peptide (39 aa, acylated)
Route
Subcutaneous (weekly)
Half-life
~5 days (SC)

Mechanism of action

Primary targetGIP and GLP-1 receptors
  1. Dual receptor activationSingle molecule activates GIP and GLP-1 receptors, weighted toward GIP.
  2. Enhanced insulin secretionGlucose-dependent insulin release with glucagon suppression.
  3. Appetite reductionCentral signaling reduces hunger and increases fullness.
  4. Slowed gastric emptyingModerates post-meal glucose and prolongs satiety.
  5. Adipose metabolism shiftGIP signaling may improve fat storage efficiency and insulin sensitivity.
Downstream effects
  • ~15–21% weight loss
  • Lower HbA1c
  • Reduced sleep apnea severity
  • Improved lipids

Researched for

  • Type 2 diabetes
  • Obesity and overweight
  • Obstructive sleep apnea
  • Heart failure with preserved ejection fraction
  • MASH (fatty liver)

Research notes

  • SURMOUNT-1 (NEJM 2022): 15.0–20.9% weight loss at 72 weeks vs 3.1% with placebo.
  • SURMOUNT-5 (NEJM 2025): 20.2% vs 13.7% weight loss compared with semaglutide at 72 weeks.
  • SURMOUNT-OSA: substantial reduction in apnea-hypopnea index, leading to the 2024 sleep apnea approval.
  • Cardiovascular outcome data are still emerging; weight regain occurs after discontinuation (SURMOUNT-4).

Reported side effects

  • Nausea, vomiting, diarrhea or constipation
  • Decreased appetite
  • Lean-mass loss alongside fat loss
  • Gallbladder disease
  • Pancreatitis (rare)

Contraindications & cautions

  • Personal or family history of medullary thyroid carcinoma
  • Multiple endocrine neoplasia type 2 (MEN2)
  • Pregnancy
  • History of pancreatitis (caution)
  • Severe gastroparesis

Lab monitoring

  • HbA1c and fasting glucose
  • Lipid panel
  • CMP (kidney and liver function)
  • Lipase if abdominal pain
  • Body composition (DEXA) to track lean mass

Dosing and pricing for Tirzepatide

Dosing references and compound pricing are available to established patients in the secure portal after a medical evaluation.

Ready to take control of your health?

Start with a 60-minute physician evaluation, virtually in seven states or in person in Reston, Virginia.

Request a consultation 703-400-5314

Cash-pay. HSA and FSA accepted. Monday–Friday, 10 AM – 2 PM (virtual and in person).